MedTrace Logo

Efficacy, Tolerability and Impact on Quality of Life of Propiverine in Patients With Overactive Bladder Syndrome

NCT02024945 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 437

Last updated 2013-12-31

No results posted yet for this study

Summary

The purposes of this study were to assess Quality of Life (QoL) and urination urge, incontinence, and micturition frequency including nocturia after 4 and 12 weeks treatment with propiverine.

Conditions

  • Overactive Bladder Syndrome

Interventions

DRUG

Propiverine

Propiverine 15 mg tablets or 30 mg regulated release capsules

Sponsors & Collaborators

Principal Investigators

  • Medical Director · Takeda

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-11-30
Primary Completion
2011-12-31
Completion
2011-12-31

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02024945 on ClinicalTrials.gov